Click for best price
Multivalent Vaccines Market Size, Share 2024
This research report provides a comprehensive analysis of the Multivalent Vaccines market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Multivalent Vaccines market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Multivalent Vaccines, challenges faced by the industry, and potential opportunities for market players.
The global Multivalent Vaccines market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Multivalent Vaccines market presents opportunities for various stakeholders, including Pediatrics, Adults. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Multivalent Vaccines market. Additionally, the growing consumer demand present avenues for market expansion.
The global Multivalent Vaccines market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The research report on the Multivalent Vaccines market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Multivalent Vaccines market.
Market Overview: The report provides a comprehensive overview of the Multivalent Vaccines market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Conjugate Vaccines, Inactivated and Subunit Vaccines), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Multivalent Vaccines market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Multivalent Vaccines market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Multivalent Vaccines market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Multivalent Vaccines market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Multivalent Vaccines market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Multivalent Vaccines market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Multivalent Vaccines, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Multivalent Vaccines market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Multivalent Vaccines market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
- Conjugate Vaccines
- Inactivated and Subunit Vaccines
- Live Attenuated Vaccines
- Toxoid Vaccines
- Recombinant Vaccines
Market segment by Application
Global Multivalent Vaccines Market Segment Percentages, By Region and Country, 2023 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Major players covered
- GlaxoSmithKline, plc (U.K.)
- Pfizer, Inc (US)
- Merck & Co., Inc (US)
- Sanofi Pasteur SA (France)
- Astellas Pharma Inc. (Japan)
- CSL Limited (Australia)
- Emergent BioSolutions, Inc (US)
- Johnson & Johnson (US)
- MedImmune, LLC (US)
- Serum Institute of India Pvt. Ltd. (India)
- Bavarian Nordic (Denmark)
- Mitsubishi Tanabe Pharma Corporation (Japan)
- Daiichi Sankyo (Japan)
- Protein Sciences Corporation (US)
- Panacea Biotec (India)
Outline of Major Chapters:
Chapter 1: Introduces the definition of Multivalent Vaccines, market overview.
Chapter 2: Global Multivalent Vaccines market size in revenue and volume.
Chapter 3: Detailed analysis of Multivalent Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Multivalent Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Multivalent Vaccines capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Multivalent Vaccines Market, Global Outlook and Forecast 2024-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
138 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Multivalent Vaccines Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Multivalent Vaccines Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Multivalent Vaccines Overall Market Size
2.1 Global Multivalent Vaccines Market Size: 2023 VS 2030
2.2 Global Multivalent Vaccines Revenue, Prospects & Forecasts: 2019-2030
2.3 Global Multivalent Vaccines Sales: 2019-2030
3 Company Landscape
3.1 Top Multivalent Vaccines Players in Global Market
3.2 Top Global Multivalent Vaccines Companies Ranked by Revenue
3.3 Global Multivalent Vaccines Revenue by Companies
3.4 Global Multivalent Vaccines Sales by Companies
3.5 Global Multivalent Vaccines Price by Manufacturer (2019-2024)
3.6 Top 3 and Top 5 Multivalent Vaccines Companies in Global Market, by Revenue in 2023
3.7 Global Manufacturers Multivalent Vaccines Product Type
3.8 Tier 1, Tier 2 and Tier 3 Multivalent Vaccines Players in Global Market
3.8.1 List of Global Tier 1 Multivalent Vaccines Companies
3.8.2 List of Global Tier 2 and Tier 3 Multivalent Vaccines Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Multivalent Vaccines Market Size Markets, 2023 & 2030
4.1.2 Conjugate Vaccines
4.1.3 Inactivated and Subunit Vaccines
4.1.4 Live Attenuated Vaccines
4.1.5 Toxoid Vaccines
4.1.6 Recombinant Vaccines
4.2 By Type - Global Multivalent Vaccines Revenue & Forecasts
4.2.1 By Type - Global Multivalent Vaccines Revenue, 2019-2024
4.2.2 By Type - Global Multivalent Vaccines Revenue, 2025-2030
4.2.3 By Type - Global Multivalent Vaccines Revenue Market Share, 2019-2030
4.3 By Type - Global Multivalent Vaccines Sales & Forecasts
4.3.1 By Type - Global Multivalent Vaccines Sales, 2019-2024
4.3.2 By Type - Global Multivalent Vaccines Sales, 2025-2030
4.3.3 By Type - Global Multivalent Vaccines Sales Market Share, 2019-2030
4.4 By Type - Global Multivalent Vaccines Price (Manufacturers Selling Prices), 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Multivalent Vaccines Market Size, 2023 & 2030
5.1.2 Pediatrics
5.1.3 Adults
5.2 By Application - Global Multivalent Vaccines Revenue & Forecasts
5.2.1 By Application - Global Multivalent Vaccines Revenue, 2019-2024
5.2.2 By Application - Global Multivalent Vaccines Revenue, 2025-2030
5.2.3 By Application - Global Multivalent Vaccines Revenue Market Share, 2019-2030
5.3 By Application - Global Multivalent Vaccines Sales & Forecasts
5.3.1 By Application - Global Multivalent Vaccines Sales, 2019-2024
5.3.2 By Application - Global Multivalent Vaccines Sales, 2025-2030
5.3.3 By Application - Global Multivalent Vaccines Sales Market Share, 2019-2030
5.4 By Application - Global Multivalent Vaccines Price (Manufacturers Selling Prices), 2019-2030
6 Sights by Region
6.1 By Region - Global Multivalent Vaccines Market Size, 2023 & 2030
6.2 By Region - Global Multivalent Vaccines Revenue & Forecasts
6.2.1 By Region - Global Multivalent Vaccines Revenue, 2019-2024
6.2.2 By Region - Global Multivalent Vaccines Revenue, 2025-2030
6.2.3 By Region - Global Multivalent Vaccines Revenue Market Share, 2019-2030
6.3 By Region - Global Multivalent Vaccines Sales & Forecasts
6.3.1 By Region - Global Multivalent Vaccines Sales, 2019-2024
6.3.2 By Region - Global Multivalent Vaccines Sales, 2025-2030
6.3.3 By Region - Global Multivalent Vaccines Sales Market Share, 2019-2030
6.4 North America
6.4.1 By Country - North America Multivalent Vaccines Revenue, 2019-2030
6.4.2 By Country - North America Multivalent Vaccines Sales, 2019-2030
6.4.3 US Multivalent Vaccines Market Size, 2019-2030
6.4.4 Canada Multivalent Vaccines Market Size, 2019-2030
6.4.5 Mexico Multivalent Vaccines Market Size, 2019-2030
6.5 Europe
6.5.1 By Country - Europe Multivalent Vaccines Revenue, 2019-2030
6.5.2 By Country - Europe Multivalent Vaccines Sales, 2019-2030
6.5.3 Germany Multivalent Vaccines Market Size, 2019-2030
6.5.4 France Multivalent Vaccines Market Size, 2019-2030
6.5.5 U.K. Multivalent Vaccines Market Size, 2019-2030
6.5.6 Italy Multivalent Vaccines Market Size, 2019-2030
6.5.7 Russia Multivalent Vaccines Market Size, 2019-2030
6.5.8 Nordic Countries Multivalent Vaccines Market Size, 2019-2030
6.5.9 Benelux Multivalent Vaccines Market Size, 2019-2030
6.6 Asia
6.6.1 By Region - Asia Multivalent Vaccines Revenue, 2019-2030
6.6.2 By Region - Asia Multivalent Vaccines Sales, 2019-2030
6.6.3 China Multivalent Vaccines Market Size, 2019-2030
6.6.4 Japan Multivalent Vaccines Market Size, 2019-2030
6.6.5 South Korea Multivalent Vaccines Market Size, 2019-2030
6.6.6 Southeast Asia Multivalent Vaccines Market Size, 2019-2030
6.6.7 India Multivalent Vaccines Market Size, 2019-2030
6.7 South America
6.7.1 By Country - South America Multivalent Vaccines Revenue, 2019-2030
6.7.2 By Country - South America Multivalent Vaccines Sales, 2019-2030
6.7.3 Brazil Multivalent Vaccines Market Size, 2019-2030
6.7.4 Argentina Multivalent Vaccines Market Size, 2019-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Multivalent Vaccines Revenue, 2019-2030
6.8.2 By Country - Middle East & Africa Multivalent Vaccines Sales, 2019-2030
6.8.3 Turkey Multivalent Vaccines Market Size, 2019-2030
6.8.4 Israel Multivalent Vaccines Market Size, 2019-2030
6.8.5 Saudi Arabia Multivalent Vaccines Market Size, 2019-2030
6.8.6 UAE Multivalent Vaccines Market Size, 2019-2030
7 Manufacturers & Brands Profiles
7.1 GlaxoSmithKline, plc (U.K.)
7.1.1 GlaxoSmithKline, plc (U.K.) Company Summary
7.1.2 GlaxoSmithKline, plc (U.K.) Business Overview
7.1.3 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Major Product Offerings
7.1.4 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales and Revenue in Global (2019-2024)
7.1.5 GlaxoSmithKline, plc (U.K.) Key News & Latest Developments
7.2 Pfizer, Inc (US)
7.2.1 Pfizer, Inc (US) Company Summary
7.2.2 Pfizer, Inc (US) Business Overview
7.2.3 Pfizer, Inc (US) Multivalent Vaccines Major Product Offerings
7.2.4 Pfizer, Inc (US) Multivalent Vaccines Sales and Revenue in Global (2019-2024)
7.2.5 Pfizer, Inc (US) Key News & Latest Developments
7.3 Merck & Co., Inc (US)
7.3.1 Merck & Co., Inc (US) Company Summary
7.3.2 Merck & Co., Inc (US) Business Overview
7.3.3 Merck & Co., Inc (US) Multivalent Vaccines Major Product Offerings
7.3.4 Merck & Co., Inc (US) Multivalent Vaccines Sales and Revenue in Global (2019-2024)
7.3.5 Merck & Co., Inc (US) Key News & Latest Developments
7.4 Sanofi Pasteur SA (France)
7.4.1 Sanofi Pasteur SA (France) Company Summary
7.4.2 Sanofi Pasteur SA (France) Business Overview
7.4.3 Sanofi Pasteur SA (France) Multivalent Vaccines Major Product Offerings
7.4.4 Sanofi Pasteur SA (France) Multivalent Vaccines Sales and Revenue in Global (2019-2024)
7.4.5 Sanofi Pasteur SA (France) Key News & Latest Developments
7.5 Astellas Pharma Inc. (Japan)
7.5.1 Astellas Pharma Inc. (Japan) Company Summary
7.5.2 Astellas Pharma Inc. (Japan) Business Overview
7.5.3 Astellas Pharma Inc. (Japan) Multivalent Vaccines Major Product Offerings
7.5.4 Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales and Revenue in Global (2019-2024)
7.5.5 Astellas Pharma Inc. (Japan) Key News & Latest Developments
7.6 CSL Limited (Australia)
7.6.1 CSL Limited (Australia) Company Summary
7.6.2 CSL Limited (Australia) Business Overview
7.6.3 CSL Limited (Australia) Multivalent Vaccines Major Product Offerings
7.6.4 CSL Limited (Australia) Multivalent Vaccines Sales and Revenue in Global (2019-2024)
7.6.5 CSL Limited (Australia) Key News & Latest Developments
7.7 Emergent BioSolutions, Inc (US)
7.7.1 Emergent BioSolutions, Inc (US) Company Summary
7.7.2 Emergent BioSolutions, Inc (US) Business Overview
7.7.3 Emergent BioSolutions, Inc (US) Multivalent Vaccines Major Product Offerings
7.7.4 Emergent BioSolutions, Inc (US) Multivalent Vaccines Sales and Revenue in Global (2019-2024)
7.7.5 Emergent BioSolutions, Inc (US) Key News & Latest Developments
7.8 Johnson & Johnson (US)
7.8.1 Johnson & Johnson (US) Company Summary
7.8.2 Johnson & Johnson (US) Business Overview
7.8.3 Johnson & Johnson (US) Multivalent Vaccines Major Product Offerings
7.8.4 Johnson & Johnson (US) Multivalent Vaccines Sales and Revenue in Global (2019-2024)
7.8.5 Johnson & Johnson (US) Key News & Latest Developments
7.9 MedImmune, LLC (US)
7.9.1 MedImmune, LLC (US) Company Summary
7.9.2 MedImmune, LLC (US) Business Overview
7.9.3 MedImmune, LLC (US) Multivalent Vaccines Major Product Offerings
7.9.4 MedImmune, LLC (US) Multivalent Vaccines Sales and Revenue in Global (2019-2024)
7.9.5 MedImmune, LLC (US) Key News & Latest Developments
7.10 Serum Institute of India Pvt. Ltd. (India)
7.10.1 Serum Institute of India Pvt. Ltd. (India) Company Summary
7.10.2 Serum Institute of India Pvt. Ltd. (India) Business Overview
7.10.3 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Major Product Offerings
7.10.4 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales and Revenue in Global (2019-2024)
7.10.5 Serum Institute of India Pvt. Ltd. (India) Key News & Latest Developments
7.11 Bavarian Nordic (Denmark)
7.11.1 Bavarian Nordic (Denmark) Company Summary
7.11.2 Bavarian Nordic (Denmark) Business Overview
7.11.3 Bavarian Nordic (Denmark) Multivalent Vaccines Major Product Offerings
7.11.4 Bavarian Nordic (Denmark) Multivalent Vaccines Sales and Revenue in Global (2019-2024)
7.11.5 Bavarian Nordic (Denmark) Key News & Latest Developments
7.12 Mitsubishi Tanabe Pharma Corporation (Japan)
7.12.1 Mitsubishi Tanabe Pharma Corporation (Japan) Company Summary
7.12.2 Mitsubishi Tanabe Pharma Corporation (Japan) Business Overview
7.12.3 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Major Product Offerings
7.12.4 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales and Revenue in Global (2019-2024)
7.12.5 Mitsubishi Tanabe Pharma Corporation (Japan) Key News & Latest Developments
7.13 Daiichi Sankyo (Japan)
7.13.1 Daiichi Sankyo (Japan) Company Summary
7.13.2 Daiichi Sankyo (Japan) Business Overview
7.13.3 Daiichi Sankyo (Japan) Multivalent Vaccines Major Product Offerings
7.13.4 Daiichi Sankyo (Japan) Multivalent Vaccines Sales and Revenue in Global (2019-2024)
7.13.5 Daiichi Sankyo (Japan) Key News & Latest Developments
7.14 Protein Sciences Corporation (US)
7.14.1 Protein Sciences Corporation (US) Company Summary
7.14.2 Protein Sciences Corporation (US) Business Overview
7.14.3 Protein Sciences Corporation (US) Multivalent Vaccines Major Product Offerings
7.14.4 Protein Sciences Corporation (US) Multivalent Vaccines Sales and Revenue in Global (2019-2024)
7.14.5 Protein Sciences Corporation (US) Key News & Latest Developments
7.15 Panacea Biotec (India)
7.15.1 Panacea Biotec (India) Company Summary
7.15.2 Panacea Biotec (India) Business Overview
7.15.3 Panacea Biotec (India) Multivalent Vaccines Major Product Offerings
7.15.4 Panacea Biotec (India) Multivalent Vaccines Sales and Revenue in Global (2019-2024)
7.15.5 Panacea Biotec (India) Key News & Latest Developments
8 Global Multivalent Vaccines Production Capacity, Analysis
8.1 Global Multivalent Vaccines Production Capacity, 2019-2030
8.2 Multivalent Vaccines Production Capacity of Key Manufacturers in Global Market
8.3 Global Multivalent Vaccines Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Multivalent Vaccines Supply Chain Analysis
10.1 Multivalent Vaccines Industry Value Chain
10.2 Multivalent Vaccines Upstream Market
10.3 Multivalent Vaccines Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Multivalent Vaccines Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Multivalent Vaccines in Global Market
Table 2. Top Multivalent Vaccines Players in Global Market, Ranking by Revenue (2023)
Table 3. Global Multivalent Vaccines Revenue by Companies, (US$, Mn), 2019-2024
Table 4. Global Multivalent Vaccines Revenue Share by Companies, 2019-2024
Table 5. Global Multivalent Vaccines Sales by Companies, (K Pcs), 2019-2024
Table 6. Global Multivalent Vaccines Sales Share by Companies, 2019-2024
Table 7. Key Manufacturers Multivalent Vaccines Price (2019-2024) & (USD/Pcs)
Table 8. Global Manufacturers Multivalent Vaccines Product Type
Table 9. List of Global Tier 1 Multivalent Vaccines Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Multivalent Vaccines Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Multivalent Vaccines Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Global Multivalent Vaccines Revenue (US$, Mn), 2019-2024
Table 13. By Type - Global Multivalent Vaccines Revenue (US$, Mn), 2025-2030
Table 14. By Type - Global Multivalent Vaccines Sales (K Pcs), 2019-2024
Table 15. By Type - Global Multivalent Vaccines Sales (K Pcs), 2025-2030
Table 16. By Application ? Global Multivalent Vaccines Revenue, (US$, Mn), 2023 & 2030
Table 17. By Application - Global Multivalent Vaccines Revenue (US$, Mn), 2019-2024
Table 18. By Application - Global Multivalent Vaccines Revenue (US$, Mn), 2025-2030
Table 19. By Application - Global Multivalent Vaccines Sales (K Pcs), 2019-2024
Table 20. By Application - Global Multivalent Vaccines Sales (K Pcs), 2025-2030
Table 21. By Region ? Global Multivalent Vaccines Revenue, (US$, Mn), 2023 VS 2030
Table 22. By Region - Global Multivalent Vaccines Revenue (US$, Mn), 2019-2024
Table 23. By Region - Global Multivalent Vaccines Revenue (US$, Mn), 2025-2030
Table 24. By Region - Global Multivalent Vaccines Sales (K Pcs), 2019-2024
Table 25. By Region - Global Multivalent Vaccines Sales (K Pcs), 2025-2030
Table 26. By Country - North America Multivalent Vaccines Revenue, (US$, Mn), 2019-2024
Table 27. By Country - North America Multivalent Vaccines Revenue, (US$, Mn), 2025-2030
Table 28. By Country - North America Multivalent Vaccines Sales, (K Pcs), 2019-2024
Table 29. By Country - North America Multivalent Vaccines Sales, (K Pcs), 2025-2030
Table 30. By Country - Europe Multivalent Vaccines Revenue, (US$, Mn), 2019-2024
Table 31. By Country - Europe Multivalent Vaccines Revenue, (US$, Mn), 2025-2030
Table 32. By Country - Europe Multivalent Vaccines Sales, (K Pcs), 2019-2024
Table 33. By Country - Europe Multivalent Vaccines Sales, (K Pcs), 2025-2030
Table 34. By Region - Asia Multivalent Vaccines Revenue, (US$, Mn), 2019-2024
Table 35. By Region - Asia Multivalent Vaccines Revenue, (US$, Mn), 2025-2030
Table 36. By Region - Asia Multivalent Vaccines Sales, (K Pcs), 2019-2024
Table 37. By Region - Asia Multivalent Vaccines Sales, (K Pcs), 2025-2030
Table 38. By Country - South America Multivalent Vaccines Revenue, (US$, Mn), 2019-2024
Table 39. By Country - South America Multivalent Vaccines Revenue, (US$, Mn), 2025-2030
Table 40. By Country - South America Multivalent Vaccines Sales, (K Pcs), 2019-2024
Table 41. By Country - South America Multivalent Vaccines Sales, (K Pcs), 2025-2030
Table 42. By Country - Middle East & Africa Multivalent Vaccines Revenue, (US$, Mn), 2019-2024
Table 43. By Country - Middle East & Africa Multivalent Vaccines Revenue, (US$, Mn), 2025-2030
Table 44. By Country - Middle East & Africa Multivalent Vaccines Sales, (K Pcs), 2019-2024
Table 45. By Country - Middle East & Africa Multivalent Vaccines Sales, (K Pcs), 2025-2030
Table 46. GlaxoSmithKline, plc (U.K.) Company Summary
Table 47. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product Offerings
Table 48. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 49. GlaxoSmithKline, plc (U.K.) Key News & Latest Developments
Table 50. Pfizer, Inc (US) Company Summary
Table 51. Pfizer, Inc (US) Multivalent Vaccines Product Offerings
Table 52. Pfizer, Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 53. Pfizer, Inc (US) Key News & Latest Developments
Table 54. Merck & Co., Inc (US) Company Summary
Table 55. Merck & Co., Inc (US) Multivalent Vaccines Product Offerings
Table 56. Merck & Co., Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 57. Merck & Co., Inc (US) Key News & Latest Developments
Table 58. Sanofi Pasteur SA (France) Company Summary
Table 59. Sanofi Pasteur SA (France) Multivalent Vaccines Product Offerings
Table 60. Sanofi Pasteur SA (France) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 61. Sanofi Pasteur SA (France) Key News & Latest Developments
Table 62. Astellas Pharma Inc. (Japan) Company Summary
Table 63. Astellas Pharma Inc. (Japan) Multivalent Vaccines Product Offerings
Table 64. Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 65. Astellas Pharma Inc. (Japan) Key News & Latest Developments
Table 66. CSL Limited (Australia) Company Summary
Table 67. CSL Limited (Australia) Multivalent Vaccines Product Offerings
Table 68. CSL Limited (Australia) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 69. CSL Limited (Australia) Key News & Latest Developments
Table 70. Emergent BioSolutions, Inc (US) Company Summary
Table 71. Emergent BioSolutions, Inc (US) Multivalent Vaccines Product Offerings
Table 72. Emergent BioSolutions, Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 73. Emergent BioSolutions, Inc (US) Key News & Latest Developments
Table 74. Johnson & Johnson (US) Company Summary
Table 75. Johnson & Johnson (US) Multivalent Vaccines Product Offerings
Table 76. Johnson & Johnson (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 77. Johnson & Johnson (US) Key News & Latest Developments
Table 78. MedImmune, LLC (US) Company Summary
Table 79. MedImmune, LLC (US) Multivalent Vaccines Product Offerings
Table 80. MedImmune, LLC (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 81. MedImmune, LLC (US) Key News & Latest Developments
Table 82. Serum Institute of India Pvt. Ltd. (India) Company Summary
Table 83. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product Offerings
Table 84. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 85. Serum Institute of India Pvt. Ltd. (India) Key News & Latest Developments
Table 86. Bavarian Nordic (Denmark) Company Summary
Table 87. Bavarian Nordic (Denmark) Multivalent Vaccines Product Offerings
Table 88. Bavarian Nordic (Denmark) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 89. Bavarian Nordic (Denmark) Key News & Latest Developments
Table 90. Mitsubishi Tanabe Pharma Corporation (Japan) Company Summary
Table 91. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product Offerings
Table 92. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 93. Mitsubishi Tanabe Pharma Corporation (Japan) Key News & Latest Developments
Table 94. Daiichi Sankyo (Japan) Company Summary
Table 95. Daiichi Sankyo (Japan) Multivalent Vaccines Product Offerings
Table 96. Daiichi Sankyo (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 97. Daiichi Sankyo (Japan) Key News & Latest Developments
Table 98. Protein Sciences Corporation (US) Company Summary
Table 99. Protein Sciences Corporation (US) Multivalent Vaccines Product Offerings
Table 100. Protein Sciences Corporation (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 101. Protein Sciences Corporation (US) Key News & Latest Developments
Table 102. Panacea Biotec (India) Company Summary
Table 103. Panacea Biotec (India) Multivalent Vaccines Product Offerings
Table 104. Panacea Biotec (India) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 105. Panacea Biotec (India) Key News & Latest Developments
Table 106. Multivalent Vaccines Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2022-2024 (K Pcs)
Table 107. Global Multivalent Vaccines Capacity Market Share of Key Manufacturers, 2022-2024
Table 108. Global Multivalent Vaccines Production by Region, 2019-2024 (K Pcs)
Table 109. Global Multivalent Vaccines Production by Region, 2025-2030 (K Pcs)
Table 110. Multivalent Vaccines Market Opportunities & Trends in Global Market
Table 111. Multivalent Vaccines Market Drivers in Global Market
Table 112. Multivalent Vaccines Market Restraints in Global Market
Table 113. Multivalent Vaccines Raw Materials
Table 114. Multivalent Vaccines Raw Materials Suppliers in Global Market
Table 115. Typical Multivalent Vaccines Downstream
Table 116. Multivalent Vaccines Downstream Clients in Global Market
Table 117. Multivalent Vaccines Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Multivalent Vaccines Segment by Type in 2023
Figure 2. Multivalent Vaccines Segment by Application in 2023
Figure 3. Global Multivalent Vaccines Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Multivalent Vaccines Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Multivalent Vaccines Revenue, 2019-2030 (US$, Mn)
Figure 7. Multivalent Vaccines Sales in Global Market: 2019-2030 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Multivalent Vaccines Revenue in 2023
Figure 9. By Type - Global Multivalent Vaccines Revenue, (US$, Mn), 2023 & 2030
Figure 10. By Type - Global Multivalent Vaccines Revenue Market Share, 2019-2030
Figure 11. By Type - Global Multivalent Vaccines Sales Market Share, 2019-2030
Figure 12. By Type - Global Multivalent Vaccines Price (USD/Pcs), 2019-2030
Figure 13. By Application - Global Multivalent Vaccines Revenue, (US$, Mn), 2023 & 2030
Figure 14. By Application - Global Multivalent Vaccines Revenue Market Share, 2019-2030
Figure 15. By Application - Global Multivalent Vaccines Sales Market Share, 2019-2030
Figure 16. By Application - Global Multivalent Vaccines Price (USD/Pcs), 2019-2030
Figure 17. By Region - Global Multivalent Vaccines Revenue, (US$, Mn), 2023 & 2030
Figure 18. By Region - Global Multivalent Vaccines Revenue Market Share, 2019 VS 2023 VS 2030
Figure 19. By Region - Global Multivalent Vaccines Revenue Market Share, 2019-2030
Figure 20. By Region - Global Multivalent Vaccines Sales Market Share, 2019-2030
Figure 21. By Country - North America Multivalent Vaccines Revenue Market Share, 2019-2030
Figure 22. By Country - North America Multivalent Vaccines Sales Market Share, 2019-2030
Figure 23. US Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 24. Canada Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 25. Mexico Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 26. By Country - Europe Multivalent Vaccines Revenue Market Share, 2019-2030
Figure 27. By Country - Europe Multivalent Vaccines Sales Market Share, 2019-2030
Figure 28. Germany Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 29. France Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 30. U.K. Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 31. Italy Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 32. Russia Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 33. Nordic Countries Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 34. Benelux Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 35. By Region - Asia Multivalent Vaccines Revenue Market Share, 2019-2030
Figure 36. By Region - Asia Multivalent Vaccines Sales Market Share, 2019-2030
Figure 37. China Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 38. Japan Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 39. South Korea Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 40. Southeast Asia Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 41. India Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 42. By Country - South America Multivalent Vaccines Revenue Market Share, 2019-2030
Figure 43. By Country - South America Multivalent Vaccines Sales Market Share, 2019-2030
Figure 44. Brazil Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 45. Argentina Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 46. By Country - Middle East & Africa Multivalent Vaccines Revenue Market Share, 2019-2030
Figure 47. By Country - Middle East & Africa Multivalent Vaccines Sales Market Share, 2019-2030
Figure 48. Turkey Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 49. Israel Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 50. Saudi Arabia Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 51. UAE Multivalent Vaccines Revenue, (US$, Mn), 2019-2030
Figure 52. Global Multivalent Vaccines Production Capacity (K Pcs), 2019-2030
Figure 53. The Percentage of Production Multivalent Vaccines by Region, 2023 VS 2030
Figure 54. Multivalent Vaccines Industry Value Chain
Figure 55. Marketing Channels
